151. [Sandimmun in the treatment of chronic glomerulonephritis with the nephrotic syndrome].
- Author
-
Krasnova TN, Tareeva IE, Shilov EM, Mukhin NA, and Miroshnichenko NG
- Subjects
- Adolescent, Adult, Chronic Disease, Cyclosporine adverse effects, Drug Evaluation, Female, Glomerulonephritis complications, Humans, Immunosuppressive Agents adverse effects, Kidney drug effects, Male, Nephrotic Syndrome etiology, Remission Induction, Time Factors, Cyclosporine therapeutic use, Glomerulonephritis drug therapy, Immunosuppressive Agents therapeutic use, Nephrotic Syndrome drug therapy
- Abstract
Sandimmun was given to 11 patients (7 males and 4 females) aged 16-34 years with chronic glomerulonephritis (CGN) and nephrotic syndrome (NS). Various morphological forms were revealed: minimal changes (MC), focal-segmentary glomerulosclerosis (FSGS), mesangiocapillary glomerulonephritis (MCGS), membraneous glomerulonephritis (MGN), mesangioproliferative glomerulonephritis (MPGN). They occurred in 1, 3, 2, 1 and 3 patients respectively. Biopsy was not made in 1 case. The duration of the disease varied from 1 to 4 years. Prior to this therapy 10 patients failed corticosteroids and cytostatics. Hypertension, high creatinine were registered in 3 and 5 patients, respectively. Sandimmun was given for 2-18 months in a daily dose 3-5 mg/kg. Serum concentration 70-180 ng/ml. After 1 to 18 months of treatment nephrotic syndrome relieved in 1 MGN, 3 MPGN, 2 FSGS, 2 MCGS patients. The recurrences were reported in 4 patients after the drug discontinuation. Serious complications were absent.
- Published
- 1997